424 related articles for article (PubMed ID: 28326600)
61. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
[TBL] [Abstract][Full Text] [Related]
62. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.
Zhou W; Jirström K; Johansson C; Amini RM; Blomqvist C; Agbaje O; Wärnberg F
BMC Cancer; 2010 Nov; 10():653. PubMed ID: 21118480
[TBL] [Abstract][Full Text] [Related]
63. Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence.
Chen XY; Thike AA; Md Nasir ND; Koh VCY; Bay BH; Tan PH
Virchows Arch; 2020 Jun; 476(6):825-833. PubMed ID: 31897820
[TBL] [Abstract][Full Text] [Related]
64. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
65. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
[TBL] [Abstract][Full Text] [Related]
66. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
67. Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast.
Rathore AS; Kumar S; Konwar R; Srivastava AN; Makker A; Goel MM
Indian J Cancer; 2013; 50(3):239-44. PubMed ID: 24061465
[TBL] [Abstract][Full Text] [Related]
68. Extent of ductal carcinoma in situ within and surrounding invasive primary breast carcinoma.
Crombie N; Rampaul RS; Pinder SE; Elston CW; Robertson JF; Ellis IO
Br J Surg; 2001 Oct; 88(10):1324-9. PubMed ID: 11578285
[TBL] [Abstract][Full Text] [Related]
69. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients.
Koh VC; Lim JC; Thike AA; Cheok PY; Thu MM; Tan VK; Tan BK; Ong KW; Ho GH; Tan WJ; Tan Y; Salahuddin AS; Busmanis I; Chong AP; Iqbal J; Thilagaratnam S; Wong JS; Tan PH
Breast Cancer Res Treat; 2015 Jul; 152(2):293-304. PubMed ID: 26077641
[TBL] [Abstract][Full Text] [Related]
70. Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced
Garaud S; Zayakin P; Buisseret L; Rulle U; Silina K; de Wind A; Van den Eyden G; Larsimont D; Willard-Gallo K; Linē A
Front Immunol; 2018; 9():2660. PubMed ID: 30515157
[TBL] [Abstract][Full Text] [Related]
71. Comparison of clinicopathological characteristics and prognosis among patients with pure invasive ductal carcinoma, invasive ductal carcinoma coexisted with invasive micropapillary carcinoma, and invasive ductal carcinoma coexisted with ductal carcinoma in situ: A retrospective cohort study.
Guan X; Xu G; Shi A; Zou Y; Zhan Y; Fan Z; Dong Y
Medicine (Baltimore); 2020 Dec; 99(50):e23487. PubMed ID: 33327281
[TBL] [Abstract][Full Text] [Related]
72. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
73. Macrophage density is an adverse prognosticator for ipsilateral recurrence in ductal carcinoma in situ.
Darvishian F; Wu Y; Ozerdem U; Chun J; Adams S; Guth A; Axelrod D; Shapiro R; Troxel AB; Schnabel F; Roses D
Breast; 2022 Aug; 64():35-40. PubMed ID: 35489232
[TBL] [Abstract][Full Text] [Related]
74. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
75. The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer.
Niwińska A; Olszewski WP
Breast Cancer Res; 2021 Dec; 23(1):118. PubMed ID: 34952631
[TBL] [Abstract][Full Text] [Related]
76. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ
Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458
[TBL] [Abstract][Full Text] [Related]
77. The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study.
Li Y; Zhang S; Wei X; Zhang J
Int J Surg; 2015 Jul; 19():91-4. PubMed ID: 26013173
[TBL] [Abstract][Full Text] [Related]
78. Ductal carcinoma in situ and ductal carcinoma in situ with microinvasion: correlation of FDG uptake with histological and biological prognostic factors.
Seo YY; Yoo IR; Park SY; Oh JK; Kim SH; Sohn HS
Breast Cancer; 2017 May; 24(3):353-361. PubMed ID: 27312540
[TBL] [Abstract][Full Text] [Related]
79. Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis.
Wu SL; Yu X; Mao X; Jin F
BMC Cancer; 2022 Jul; 22(1):782. PubMed ID: 35843951
[TBL] [Abstract][Full Text] [Related]
80. Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.
Miligy IM; Toss MS; Gorringe KL; Ellis IO; Green AR; Rakha EA
Pathobiology; 2022; 89(6):382-392. PubMed ID: 35533650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
